• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高血糖与血管代谢记忆:真相还是虚构?

Hyperglycemia and vascular metabolic memory: truth or fiction?

机构信息

Department of Clinical and Experimental Medicine, Section of Diabetes and Metabolic Diseases, Nuovo Ospedale Santa Chiara, Via Paradisa, 2, 56124 Pisa, Italy.

出版信息

Curr Diab Rep. 2013 Jun;13(3):403-10. doi: 10.1007/s11892-013-0371-2.

DOI:10.1007/s11892-013-0371-2
PMID:23456482
Abstract

Prevention of long-term complications remains the main challenge in the treatment of diabetes. A strong relationship between glucose control and development of complications is apparent in all epidemiologic studies. Yet, intervention trials have yielded questionable results, particularly when intensive treatment was introduced in patients with long-standing diabetes. It has been postulated that in these subjects, prior exposure to chronic hyperglycemia may have generated a negative "metabolic memory," preventing full exertion of the beneficial effects of any subsequent improvement of glucose control. This phenomenon has been replicated in animal models and it recognizes a molecular basis in the role of oxidative stress, advanced glycation processes, and epigenetic mechanisms accounting for self-perpetuating modifications of gene expression. Conversely, early intervention in both type 1 and type 2 diabetes has proven that good glycemic control reduces the risk of development and progression of complications with a beneficial effect that extends well beyond the duration of near-normoglycemia. This has brought up the concept of "metabolic legacy," an advantage handed down by early and effective implementation of treatments designed to reduce blood glucose levels as safely as possible along with multifactorial intervention of all cardiovascular risk factors. The evidence, nature, and clinical implication of these concepts are reviewed.

摘要

预防长期并发症仍然是糖尿病治疗的主要挑战。所有的流行病学研究都表明,血糖控制与并发症的发展之间存在着密切的关系。然而,干预试验的结果却令人怀疑,特别是当在长期患有糖尿病的患者中引入强化治疗时。有人推测,在这些患者中,先前暴露于慢性高血糖可能产生了负面的“代谢记忆”,从而阻止了随后任何改善血糖控制的有益效果的充分发挥。这一现象在动物模型中得到了复制,并在氧化应激、糖基化终产物和表观遗传机制在解释基因表达的自我持续修饰中的作用中找到了分子基础。相反,1 型和 2 型糖尿病的早期干预已经证明,良好的血糖控制可以降低并发症的发生和进展的风险,其有益效果远远超出了接近正常血糖的持续时间。这就提出了“代谢遗产”的概念,即通过尽早和有效地实施旨在尽可能安全地降低血糖水平的治疗以及对所有心血管危险因素的多因素干预,所带来的优势。本文回顾了这些概念的证据、性质和临床意义。

相似文献

1
Hyperglycemia and vascular metabolic memory: truth or fiction?高血糖与血管代谢记忆:真相还是虚构?
Curr Diab Rep. 2013 Jun;13(3):403-10. doi: 10.1007/s11892-013-0371-2.
2
Metabolic memory: Evolving concepts.代谢记忆:不断发展的概念。
J Diabetes. 2018 Mar;10(3):186-187. doi: 10.1111/1753-0407.12622. Epub 2017 Dec 11.
3
The "Metabolic Memory" Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications.“代谢记忆”理论与高血糖的早期治疗对预防糖尿病并发症的作用
Nutrients. 2017 Apr 28;9(5):437. doi: 10.3390/nu9050437.
4
Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms.代谢记忆与糖尿病肾病:表观遗传机制的潜在作用。
Nat Rev Nephrol. 2010 Jun;6(6):332-41. doi: 10.1038/nrneph.2010.55. Epub 2010 Apr 27.
5
The role of "metabolic memory" in the natural history of diabetes mellitus.“代谢记忆”在糖尿病自然病程中的作用。
Pol Arch Med Wewn. 2009 Jul-Aug;119(7-8):493-500.
6
Epigenetic phenomena linked to diabetic complications.与糖尿病并发症相关的表观遗传现象。
Nat Rev Endocrinol. 2010 Dec;6(12):665-75. doi: 10.1038/nrendo.2010.188. Epub 2010 Nov 2.
7
Glycemic memories and the epigenetic component of diabetic nephropathy.血糖记忆与糖尿病肾病的表观遗传组分。
Curr Diab Rep. 2013 Aug;13(4):574-81. doi: 10.1007/s11892-013-0383-y.
8
Glycemic exposure, glycemic control, and metabolic karma in diabetic complications.糖尿病并发症中的血糖暴露、血糖控制与代谢因果关系
Adv Chronic Kidney Dis. 2014 May;21(3):311-7. doi: 10.1053/j.ackd.2014.03.004.
9
Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes.阻断晚期糖基化终末产物(AGEs)及其受体(RAGE)系统可能是多因素干预对2型糖尿病死亡率产生持续有益影响的一种机制。
Med Hypotheses. 2008 Nov;71(5):749-51. doi: 10.1016/j.mehy.2008.05.039. Epub 2008 Aug 16.
10
Metabolic memory: a vascular perspective.代谢记忆:血管视角。
Cardiovasc Diabetol. 2010 Sep 14;9:51. doi: 10.1186/1475-2840-9-51.

引用本文的文献

1
Diabetes Mellitus and Associated Vascular Disease: Pathogenesis, Complications, and Evolving Treatments.糖尿病及相关血管疾病:发病机制、并发症与不断发展的治疗方法
Adv Ther. 2025 Jun;42(6):2659-2678. doi: 10.1007/s12325-025-03185-9. Epub 2025 Apr 19.
2
Glycemic Comparison Index (GCI): a retrospective analysis of its prognostic value in ICU patients with AMI and diabetes.血糖比较指数(GCI):对其在合并急性心肌梗死和糖尿病的重症监护病房患者中的预后价值的回顾性分析
BMC Endocr Disord. 2025 Mar 26;25(1):85. doi: 10.1186/s12902-025-01907-2.
3
Subcellular mass spectrometric detection unveils hyperglycemic memory in the diabetic heart.

本文引用的文献

1
Association between cardiovascular autonomic neuropathy and left ventricular dysfunction: DCCT/EDIC study (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications).心血管自主神经病变与左心室功能障碍的关系:DCCT/EDIC 研究(糖尿病控制与并发症试验/糖尿病干预和并发症的流行病学)。
J Am Coll Cardiol. 2013 Jan 29;61(4):447-454. doi: 10.1016/j.jacc.2012.10.028. Epub 2012 Dec 19.
2
Primary prevention of macroangiopathy in patients with short-duration type 2 diabetes by intensified multifactorial intervention: seven-year follow-up of diabetes complications in Chinese.强化多因素干预对短期 2 型糖尿病患者大血管病变的一级预防:中国糖尿病并发症研究七年随访。
Diabetes Care. 2013 Apr;36(4):978-84. doi: 10.2337/dc12-0227. Epub 2012 Dec 10.
3
亚细胞质谱检测揭示糖尿病心脏中的高血糖记忆。
J Diabetes. 2024 Nov;16(11):e70033. doi: 10.1111/1753-0407.70033.
4
Metabolomics analysis of serum and urine in type 1 diabetes patients with different time in range derived from continuous glucose monitoring.对通过持续葡萄糖监测得出的不同血糖在目标范围内时间的1型糖尿病患者的血清和尿液进行代谢组学分析。
Diabetol Metab Syndr. 2024 Jan 19;16(1):21. doi: 10.1186/s13098-024-01257-4.
5
Positive feedback loop of miR-320 and CD36 regulates the hyperglycemic memory-induced diabetic diastolic cardiac dysfunction.miR-320与CD36的正反馈回路调节高血糖记忆诱导的糖尿病性舒张性心脏功能障碍。
Mol Ther Nucleic Acids. 2022 Dec 14;31:122-138. doi: 10.1016/j.omtn.2022.12.009. eCollection 2023 Mar 14.
6
The efficacy and safety of dachaihu decoction in the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis.大柴胡汤治疗2型糖尿病的疗效与安全性:一项系统评价与Meta分析
Front Pharmacol. 2022 Aug 8;13:918681. doi: 10.3389/fphar.2022.918681. eCollection 2022.
7
The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases.晚期糖基化终产物及其可溶性受体在肾脏疾病中的作用。
Int J Mol Sci. 2022 Mar 22;23(7):3439. doi: 10.3390/ijms23073439.
8
Adipocyte Phenotype Flexibility and Lipid Dysregulation.脂肪细胞表型的灵活性与脂代谢紊乱
Cells. 2022 Mar 3;11(5):882. doi: 10.3390/cells11050882.
9
The association between trajectories of risk factors and risk of cardiovascular disease or mortality among patients with diabetes or hypertension: A systematic review.糖尿病或高血压患者的风险因素轨迹与心血管疾病或死亡率风险之间的关联:系统评价。
PLoS One. 2022 Jan 27;17(1):e0262885. doi: 10.1371/journal.pone.0262885. eCollection 2022.
10
Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes.晚期糖基化终产物预测 2 型糖尿病患者肾功能丧失和高危慢性肾脏病。
Diabetes Care. 2022 Mar 1;45(3):684-691. doi: 10.2337/dc21-2196.
Basal insulin and cardiovascular and other outcomes in dysglycemia.基础胰岛素与糖调节受损患者的心血管及其他结局。
N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.
4
Prevalence and risk factors for diabetic microvascular complications in newly diagnosed type II diabetes mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 27).新诊断的 2 型糖尿病患者中糖尿病微血管并发症的患病率及其危险因素。Sankara Nethralaya 糖尿病视网膜病变流行病学和分子遗传学研究(SN-DREAMS,报告 27)。
J Diabetes Complications. 2012 Mar-Apr;26(2):123-8. doi: 10.1016/j.jdiacomp.2012.02.001. Epub 2012 Mar 24.
5
Intensive glucose-lowering therapy in people with type 2 diabetes: what do we learn from a new meta-analysis of randomised controlled trials?
Evid Based Med. 2012 Jun;17(3):98-9. doi: 10.1136/ebmed-2011-100230. Epub 2011 Nov 28.
6
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.1 型糖尿病的强化糖尿病治疗与肾小球滤过率。
N Engl J Med. 2011 Dec 22;365(25):2366-76. doi: 10.1056/NEJMoa1111732. Epub 2011 Nov 12.
7
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants.1980 年以来,空腹血糖和糖尿病患病率的国家、地区和全球趋势:对 370 个国家和地区年以及 270 万参与者的健康检查调查和流行病学研究的系统分析。
Lancet. 2011 Jul 2;378(9785):31-40. doi: 10.1016/S0140-6736(11)60679-X. Epub 2011 Jun 24.
8
Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial.早期强化多因素治疗对筛查出的 2 型糖尿病患者 5 年心血管结局的影响(ADDITION-Europe):一项集群随机试验。
Lancet. 2011 Jul 9;378(9786):156-67. doi: 10.1016/S0140-6736(11)60698-3. Epub 2011 Jun 24.
9
Diabetes mellitus, fasting glucose, and risk of cause-specific death.糖尿病、空腹血糖与特定病因死亡风险。
N Engl J Med. 2011 Mar 3;364(9):829-841. doi: 10.1056/NEJMoa1008862.
10
Long-term effects of intensive glucose lowering on cardiovascular outcomes.强化血糖控制对心血管结局的长期影响。
N Engl J Med. 2011 Mar 3;364(9):818-28. doi: 10.1056/NEJMoa1006524.